BioSpace News Archive

Businesswoman running arrow path breaking barriers of inequality, feminism, overcoming women's obstacles. and leadership. isometric vector illustration.

5 molecular glues that could stick—and the companies stuck in

Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.

July 6, 2026

·

6 min read

·

Michael Gibney

Creative photo collage geometry figures scales platform weight hands body fragments pointing finger stability spheres measure.

FDA

Despite chaos and churn, FDA decisions hold mostly steady in H1 2026

Significant leadership instability at the FDA—compounded by continued workforce attrition—led to a slight slowdown in overall regulatory productivity in the first half of this year, but the agency has been catching up of late.

July 6, 2026

·

8 min read

·

Tristan Manalac

China USA Trade War Risk and Beijing Washington Crisis as Chinese and American retaliatory tariffs as a Financial risk and investment danger as stock market turbulence as a paper boat representing global exports and imports challenges.

Opinion

The FDA must put biotech at its center or continue to cede early research to China

Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.

July 6, 2026

·

4 min read

·

Kendalle Burlin O’Connell

Press Releases

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

July 6, 2026

·

6 min read

Press Releases

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform